On November 7, 2019 AgilVax Inc., reported that Joseph Patti, PhD, President and Chief Executive Officer, will present an overview of the Company and provide an update on its portfolio of targeted antibody-based therapies addressing multiple cancers at the NYC Oncology Investor Conference on November 12, 2019 at 5:30 PM (ET) (Press release, Agilvax, NOV 7, 2019, View Source [SID1234550664]). The conference is being held at the Perkins Coie law firm, 1155 6th Ave, New York City, NY.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AgilVax has demonstrated in preclinical in vivo models that antibodies to xCT were able to reduce primary tumor formation and the number of lung metastases. xCT overexpression occurs in several cancers leading to metabolic changes that reprograms cells for growth and progression. AgilVax has multiple solutions to target cancer cells that overexpress xCT and when used in combination with existing therapies or alone have the potential to create a durable response in patients suffering from colorectal and other metastatic cancers.